FDA Inspection 1220071 — Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. — FEI 3012279857

The FDA completed an inspection of Hikma Pharmaceuticals USA Inc. on Sep 29, 2023 in Bedford, OH. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). 2 citations were issued during this inspection. Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 29, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Bedford, OH (United States)

Citations

IDCFRDescription
145221 CFR 211.113(b)Validation lacking for sterile drug products
440221 CFR 211.192Written record of investigation incomplete

Need the full FDA record for Hikma Pharmaceuticals USA Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.